Executive Byron Robinson exits Janux Therapeutics (NASDAQ: JANX) as CSO

Rhea-AI Filing Summary

Janux Therapeutics, Inc. reported that Byron Robinson, Ph.D., a previously named executive officer, has left the company. He ceased serving as Chief Strategy Officer and departed effective September 18, 2025. The company determined that his departure qualifies as a termination without “Cause” under its Change in Control and Severance Benefit Plan, which may entitle him to certain severance benefits pursuant to that plan. The filing does not announce any new appointment to the Chief Strategy Officer role.

Insights

Corporate governance and biotech leadership analyst

Janux discloses the without-cause departure of its former Chief Strategy Officer.

The company states that Byron Robinson, Ph.D., a previously named executive officer, ended his role as Chief Strategy Officer and departed effective September 18, 2025. The departure is classified as a termination without “Cause” under Janux’s Change in Control and Severance Benefit Plan, indicating that standard severance protections may apply rather than a performance- or misconduct-related termination.

For investors, this is primarily a governance and management-structure update rather than a quantified financial event. The filing does not provide information on a successor or changes to strategic priorities, so the immediate implications for operations or R&D focus are not detailed here. Subsequent disclosures in company communications or future SEC filings may clarify any broader strategic impact of this leadership change.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false000181771300018177132025-09-182025-09-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

Janux Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-40475	82-2289112
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
10955 Vista Sorrento Parkway, Suite 200 San Diego, California		92130
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 751-4493

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		JANX		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc. (the “Company”), ceased to serve as Chief Strategy Officer of the Company and departed from the Company effective September 18, 2025 under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (File No. 333-256297), filed with the Securities and Exchange Commission on May 19, 2021).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		JANUX THERAPEUTICS, INC.
Date: September 19, 2025		By:	/s/ David Campbell, Ph.D.
			David Campbell, Ph.D.
			President and Chief Executive Officer

FAQ

What did Janux Therapeutics (JANX) announce in this 8-K filing?

Janux Therapeutics, Inc. announced that Byron Robinson, Ph.D., previously a named executive officer, ceased to serve as Chief Strategy Officer and departed the company effective September 18, 2025.

Who is the executive departing Janux Therapeutics (JANX)?

The departing executive is Byron Robinson, Ph.D., who had served as Chief Strategy Officer and was previously identified as a named executive officer of Janux Therapeutics, Inc.

How was Byron Robinson’s departure from Janux Therapeutics (JANX) classified?

Janux determined that Byron Robinson’s departure constitutes a termination without “Cause” under the company’s Change in Control and Severance Benefit Plan.

When did the Chief Strategy Officer’s departure from Janux Therapeutics (JANX) become effective?

His departure from the role of Chief Strategy Officer and from the company became effective on September 18, 2025.

Does Janux Therapeutics (JANX) reference any agreements related to the executive’s severance?

Yes. The company references its Change in Control and Severance Benefit Plan, previously filed as Exhibit 10.12 to its Registration Statement on Form S-1, as the governing document for the termination without “Cause.”

Does the filing name a replacement Chief Strategy Officer at Janux Therapeutics (JANX)?

No. The filing states that Byron Robinson, Ph.D. ceased to serve as Chief Strategy Officer and departed but does not identify a successor to that role.